Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
Medindia6d
FDA Approves EBGLYSS Drug for Atopic Dermatitis in Adults and Children
EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...
Eli Lilly’s EBGLYSS offers long-term disease control in atopic dermatitis trial
Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...
PMLiVE6d
Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis
Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...
Eli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
stocknews5d
3 Healthcare Stocks to Watch as the Aging Population Drives Demand
As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...
The Motley Fool4d
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
Certain economic sectors tend to be more resilient in an uncertain macroeconomic climate. Pharmaceutical giant Eli Lilly owns a portfolio of mainstay and emerging blockbuster drugs. Lululemon ...